Oxaliplatin|[sol]|capecitabine vs oxaliplatin|[sol]|infusional 5-FU in advanced colorectal cancer: the MRC COIN trial

Intravenous (IV) 5-FU has been the backbone of treatment for advanced colorectal cancer (aCRC) for over 40 years. Currently capecitabine, an oral fluoropyrimidine (Fp) prodrug, is commonly used as a convenient and effective alternative. Two large phase III randomised trials compared capecitabine 1250 mg m−2 twice daily for 14 days repeated every 3 weeks to the Mayo Clinic regimen (Mayo) of IV leucovorin (LV) 20 mg m−2 followed by daily bolus 5-FU 425 mg m−2 for 5 days repeated every 4 weeks. Integrated data analysis of the two trials has shown similar overall survival (OS) and progression free survival (PFS) between the two regimens (Van Cutsem et al, 2004). In comparison with Mayo, capecitabine appeared to have a better toxicity profile and to be a safer treatment option for patients with moderate renal impairment. It was also shown that the standard starting dose of capecitabine was safe for patients with mild renal impairment; however, it was recommended that such patients should be monitored closely with prompt treatment interruption and dose reduction in the event of a grade 2 or higher toxicity (Cassidy et al, 2002). Bolus 5-FU has largely been replaced with a continuous infusion in current treatment regimens. The de Gramont (LV5FU2) regimen of LV/infusional 5FU was compared with Mayo in a randomised trial. LV5FU2 was not only less toxic but was also associated with a better response rate (RR) and PFS (de Gramont et al, 1997). Oxaliplatin is used in combination with either 5-FU (OxFU) or capecitabine (OxCap). Several phase III studies have compared OxFU with OxCap as first-line treatment for aCRC including: the German AIO (Porschen et al, 2007), the Spanish TTD (Diaz-Rubio et al, 2007), the international NO16966 (Cassidy et al, 2008) and the French FNCLCC (Ducreux et al, 2011). All four of these trials, together with two smaller ones, were included in a meta-analysis that showed similar PFS and OS but an inferior overall RR (ORR) for OxCap. Thrombocytopenia, diarrhoea and palmar-plantar erythema (PPE) were more prominent with OxCap-based regimens whereas neutropenia was more prominent with OxFU (Arkenau et al, 2008). COIN is a three-arm multi-centre phase III open-label randomised controlled trial of the MRC, London. It compared standard continuous chemotherapy with OxFU or OxCap (Arm A) to each of two experimental arms: same chemotherapy plus cetuximab (Arm B) or intermittent chemotherapy without cetuximab (Arm C). The choice between OxFU and OxCap was nonrandomised but was agreed between the patient and treating clinician before randomisation. COIN did not meet either of its primary outcome measures as the addition of cetuximab was not associated with an improvement in efficacy (Maughan et al, 2011), and intermittent chemotherapy was not confirmed to be non-inferior to continuous treatment (Adams et al, 2011). We report a retrospective analysis comparing OxCap with OxFU and OxCap+cetuximab with OxFU+cetuximab in terms of efficacy and severe side effects. We also examine the success of switching from one OxFp regimen to the alternate as a strategy for keeping patients on first-line treatment in case of intolerance to the first regimen chosen. Following the recommendation from Cassidy et al (2002) to monitor patients with mild renal impairment, we investigate the effect of renal impairment on toxicity on both OxFp regimens. None of these analyses were pre-specified in the COIN trial protocol. OxFU was a 2-weekly regimen of IV L-LV 175 or D,L-LV 350 mg given concurrently with oxaliplatin 85 mg m−2 over 2 h on day 1, followed by IV bolus 5-FU 400 mg m−2 and finally 5-FU 2400 mg m−2 infused over 46 h. This regimen requires an indwelling venous line (IVL) and is referred to as OxMdG in the United Kingdom. Switching from one regimen to another was allowed for toxicity, compliance, logistics or patient’s choice. All patients switching from OxFU to OxCap had their dose of capecitabine reduced to 850 mg m−2 in the first cycle as the retained intracellular LV can potentially increase capecitabine toxicity (Hennig et al, 2008). In Arm B, cetuximab was given in a loading dose of 400 mg m−2 IV over 2 h on day 1 and subsequently at 250 mg m−2 over 1 h once a week. Response was assessed every 12 weeks using the RECIST 1.0 criteria. In both Arms A and B, treatment was continued until disease progression, unacceptable toxicities or patient’s choice. In Arm C, treatment was stopped after 12 weeks and patients with responding or stable disease had a break from chemotherapy but this was restarted on evidence of clinical or radiological disease progression. An unlimited number of 12 week courses were allowed until evidence of treatment failure, which is defined as disease progression on or shortly after stopping treatment. Patients were classified according to the chemotherapy regimen (OxCap or OxFU) used in their first cycle. Those who did not receive any trial treatment were excluded from all analyses and those who switched regimen were included in toxicity analyses for toxicities of the first regimen, but were excluded from all efficacy analyses. OxCap was regarded as the control group for HR and OR calculations. Pearson’s χ2 tests were used to calculate P-values, and for cells with low count (n<5) Fisher’s exact test was used instead; P-values <0.05 were considered significant. Survival curves were plotted using the Kaplan–Meier method. Unadjusted and stratified HR was estimated using the Peto log-rank method, and OR using the Mantel–Haenszel method. For adjusted HR and OR, Cox and logistic regressions were used, respectively. Efficacy and toxicity outcome measures were corrected for predefined prognostic factors (PFs), and whenever arms were combined correction was also made for trial arm membership. PFs for toxicity were determined through the same procedure using the outcome ‘any G3+ toxicity vs none’. These were as follows: CrCl, age and WHO PS. In total, 118 patients (5%) had a change in Fp regimen during trial treatment, 59 in each group corresponding to 4% and 7% of patients on OxCap (±cetuximab) and OxFU (±cetuximab), respectively. Reasons for switching regimen were (% out of patients who switched): IVL complications 0 (0%) and 42 (71%), toxicity (not further specified by centres) 45 (76%) and 6 (10%), and patient’s choice or compliance issues 13 (22%) and 10 (17%) of patients on OxCap (±cetuximab) and OxFU (±cetuximab), respectively; the reason was unknown for 1 patient in each group (2%). χ2 test for difference in distribution of reasons=72.2 on 2 degrees of freedom; P<0.001. Although all patients who switched from OxCap (±cetuximab) remained on OxFU (±cetuximab) until they came off trial, 13 (22%) of those who switched from OxFU (±cetuximab) later returned to their original regimen after receiving, on average, two OxCap cycles. In most cases this was a temporary measure after the IVL was removed, due to a complication, to avoid treatment delays or the need for IVL re-insertion when patients in Arm C were about to go on a treatment break. There was no excess of intolerance to the second regimen in patients who switched regimen once: 17 patients (16%) out of this group came off trial due to toxicity or patient’s choice compared with 436 (19%) of those who never switched (P=0.45). OS was similar between OxCap+cetuximab and OxFU+cetuximab but PFS was longer for OxFU+cetuximab at 8.5 compared with 7.4 months for OxCap+cetuximab: adjusted HR 0.79 (0.67, 0.93). Progression free survival analysis was repeated using only patients who were randomised before capecitabine dose reduction was mandated for Arm B but the pattern stayed the same: adjusted HR 0.79 (0.65, 0.94), P=0.010. Across all arms, 119 patients (5%) in the efficacy sample underwent radical surgery, of which 74% were liver metastasectomies, 13% lung metastasectomies, 9% primary resections (with or without liver metastasectomy) and 4% other sites. Rate of radical surgeries was higher for OxFU (6.5%) compared with OxCap (3.5%): adjusted OR 1.96 (1.18, 3.23) whereas RRS was similar between OxFU+cetuximab and OxCap+cetuximab. In the OxFU group, there was no statistically significant difference for any of the toxicities or in dose modification between the two CrCl groups. In the OxCap+cetuximab group, patients with CrCl 50–80 ml min−1 had a higher rate of G3+ lethargy (29% vs 17%) and more reductions in the capecitabine dose (67% vs 53%) compared with those of CrCl >80 ml min−1. In the OxFU+cetuximab group, G3+ neutropenia was higher in patients with CrCl 50–80 ml min−1 compared with those of CrCl >80 ml min−1 (36% vs 23%) and so were the rates of dose delays (76% vs 66%) and reductions for both oxaliplatin (39% vs 26%) and 5-FU (56% vs 39%). There was no difference in treatment-related deaths in any of the comparisons. This paper compared OxCap with OxFU given in the XELOX and OxMdG regimens, respectively. The latter regimen is widely used in the United Kingdom and is similar to FOLFOX6 (Braun et al, 2003). XELOX and FOLFOX6 were compared in the French study reported by Ducreux et al (2011), which showed in a per protocol analysis that XELOX is non-inferior to FOLFOX6 in terms of ORR (primary outcome measure), PFS and OS. Our retrospective analysis of the COIN data confirms that OxCap (XELOX) is equivalent to OxFU (OxMdG) in terms of the three efficacy measures, and is overall in line with the results of the meta-analysis by Arkenau et al (2008). However, the meta-analysis demonstrated an inferior ORR for OxCap (OR 0.85; 95% CI 0.74–0.97). Both ORR and RRS in our study were numerically higher for OxFU; this reached statistical significance for RRS but not ORR despite the size of the study. OxFU+cetuximab and OxCap+cetuximab were also equivalent in terms of OS, ORR and RRS. Nonetheless, PFS was longer for OxFU+cetuximab and this remained the case after repeating the analyses using only patients who were randomised before the protocol mandated capecitabine dose reduction. This observation is consistent with the positive interaction for cetuximab with the Fp partner in favour of 5-FU, which was demonstrated by the exploratory analyses of Arm B vs Arm A (Maughan et al, 2011). A possible explanation would be the higher toxicity for OxCap+cetuximab, which led to more dose reductions and a lower total dose of oxaliplatin: 682 mg for OxCap+cetuximab vs 806 mg for OxFU+cetuximab. Our study also confirmed that OxCap and OxFU have different toxicity profiles with OxFU being associated with higher rates of G3+ mucositis, neutropenia and treatment-related infections, and OxCap being associated with higher rates of G3+ nausea, diarrhoea and PPE. Of note, more patients on OxFU had G3+ neuropathy, which was limited to Arm A in the individual arm analysis: 22% vs 16% for patients on OxFU and OxCap, respectively. This may be explained by the 6% higher cumulative dose of oxaliplatin for patients on OxFU compared with OxCap in Arm A: 848 and 797 mg, respectively. The rate of patients who came off their second regimen after switching from OxFU (±cetuximab) to OxCap (±cetuximab) or vice versa was only 16%. This success in switching from one regimen to the other in keeping patients on first-line chemotherapy can be explained by the differing acceptability to patients of specific toxicity profiles. Patients with CrCl 50–80 ml min−1 on OxCap had more G3+ toxicities and dose delays compared with those of CrCl >80 ml min−1. This discrepancy was not observed between the two CrCl groups in patients on OxFU. However, patients on OxFU+cetuximab with mild renal impairment required more dose modifications compared with patients of CrCl >80 ml min−1 on the same regimen. In conclusion: (I) OxFU (OxMdG) and OxCap (XELOX) have similar efficacy in the first-line treatment for aCRC. (II) OxFU is a better chemotherapy partner for cetuximab than OxCap because of less diarrhoea and longer PFS. (III) Toxicity patterns differ and thus the risks and preferences for the individual patient should inform the choice between OxCap and OxFU regimens. (IV) Switching to a different oxaliplatin/Fp regimen is a valid option in the event of controlled disease but poor tolerance or compliance and should be considered before abandoning this regimen and moving to a second-line regimen. (V) Patients with mild renal impairment on OxCap or OxFU+cetuximab should be monitored closely for the development of severe toxicities and early and appropriate dose reduction should be instituted if they occur. The authors declare no conflict of interest. We are indebted to the 2445 patients and their families who participated in COIN. The design of the Medical Research Council (MRC) COIN trial was conceived and developed by the National Cancer Research Institute aCRC group. The trial was funded by the peer-reviewed Cancer Research UK Clinical Trials Advisory and Awards Committee, the MRC and an unrestricted educational grant from Merck kGaA. Additional support in the form of discounted products was provided by Sanofi, Wyeth and Baxter. The MRC was the overall sponsor of the study, with some responsibilities for the Republic of Ireland sites delegated to the All Ireland Cooperative Clinical Research Group. COIN was approved by the Medicines and Healthcare Regulatory Agency in June 2004 and South-West Multi-Centre Research Ethics Committee in December 2004. Approvals for the Irish sites were obtained from the Irish Medicines Board in November 2006 and SJH/AMNCH Research Ethics Committee in December 2006. The trial was coordinated by the MRC Clinical Trials Unit (CTU) following the principles of GCP, conducted with a Trial Management Group, monitored at regular intervals by an Independent Data Monitoring Committee and overseen by an independent Trial Steering Committee. Data collection at UK sites was supported by staff funding from the National Cancer Research Networks. All statistical analyses were performed at the MRC CTU. The trial is registered as an International Standard Randomised Controlled trial, number ISRCTN27286448. Tumour mutation analysis was performed at the Institute of Medical Genetics, Cardiff University.